ENSYSCE BIOSCIENCE WTS - ENSCW STOCK NEWS

Ensysce Biosciences has renewed its collaboration with Quotient Sciences to advance the clinical development of its overdose protection platform, PF614-MPAR. This innovative opioid product, designed to prevent overdose by shutting off opioid release when too many pills are ingested, is undergoing a Phase 1b study to evaluate its efficacy and safety across different doses. The study, PF614-MPAR-102, will assess doses of 25 mg, 50 mg, and 100 mg administered twice daily for five days. PF614-MPAR, which has received Breakthrough Therapy designation from the FDA, aims to provide a safer solution for severe pain management and address the ongoing opioid overdose crisis in the U.S.

Ensysce Biosciences reported their first quarter 2024 financial results, highlighting progress in their clinical programs with FDA breakthrough therapy designations for their lead opioid products, PF614 and PF614-MPAR. The company received positive feedback and guidance from the FDA, affirming their path to regulatory approval and commercialization. Ensysce is set to begin Phase 3 clinical trials in the second half of 2024, showcasing their innovative TAAP and MPAR opioids for severe pain relief with reduced abuse potential.

Ensysce Biosciences, a clinical stage pharmaceutical company (NASDAQ: ENSC), presented at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference. The webcast discussed the Company's innovative solutions for pain relief with reduced opioid abuse risk. CEO Dr. Lynn Kirkpatrick highlighted TAAP and MPAR technology, lead drug candidates PF614 and PF614-MPAR, FDA Breakthrough Therapy designation for PF614-MPAR, and upcoming milestones.

Ensysce Biosciences, Inc. (ENSC) announces participation in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference. The company focuses on developing innovative solutions for severe pain relief while reducing opioid misuse. Dr. Lynn Kirkpatrick and Dave Humphrey will present at the conference, offering a Q&A session. Attendees can register for the event for free and access the webcast later. Ensysce's management team will also be available for one-on-one meetings.

Ensysce Biosciences, Inc. announces positive results from the clinical study PF614-102 comparing PF614, a novel TAAP prodrug of oxycodone, to OxyContin. The study demonstrates a clear dose relationship between PF614 and oxycodone, achieving bioequivalence with OxyContin. PF614 offers advantages such as similar oxycodone exposures in fasted and fed states, a longer half-life, and potential as a twice-daily pain treatment. The manuscript published in Clinical and Translational Science highlights the safety and pharmacokinetics profile of PF614, positioning it as a promising analgesic for severe pain.

Ensysce Biosciences, Inc. announces the presentation of their lead product, PF614-MPAR, at the NIH HEAL Initiative Scientific Meeting. The drug has been granted Breakthrough Therapy Designation by the FDA and has received funding from NIDA. The company aims to combat abuse and protect against oral opioid overdose, addressing the current opioid crisis. The presentation of the trial data reflects the successful optimization of the drug product, with potential to become a first-in-class 'Next Generation' opioid with abuse deterrent and oral overdose protection properties.

Ensysce Biosciences, Inc. (NASDAQ: ENSC) made significant progress in 2023, focusing on delivering innovative approaches to severe pain with the unique benefit of overdose protection. The company aims to move its lead analgesic through to commercialization and expand its pipeline of products to treat pain. CEO Dr. Lynn Kirkpatrick expressed gratitude for shareholder support and outlined the corporate and clinical milestones achieved in the past year, with a focus on a transformational year in 2024.

Ensysce Biosciences, Inc. (NASDAQ:ENSC) announced the completion of enrollment for the PF614-201 study, a critical step towards Phase 3 evaluation of PF614. The study aims to confirm the onset time for PF614 analgesic effects, with trial results expected in December 2023. The company's Chief Medical Officer highlighted the significance of this milestone, emphasizing the potential of PF614 to provide longer and safer exposure to analgesic levels compared to OxyContin, with lower abuse potential.

Ensysce Biosciences, Inc. has entered into a securities purchase agreement with investors for an aggregate investment of $1.7 million. The funding will support the clinical development of their lead product and advance their unique technologies. The Notes are convertible into shares of Ensysce common stock at a conversion price of $1.5675 and the Warrants have the right to purchase up to 1,255,697 shares of common stock at an exercise price of $1.5675.